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Matrix metalloproteinase 11 
protects from diabesity and 
promotes metabolic switch
Nassim Dali-Youcef1,2, Karim Hnia3,4,*, Sébastien Blaise1,†,*, Nadia Messaddeq5, 
Stéphane Blanc6, Catherine Postic7, Philippe Valet4, Catherine Tomasetto1 &  
Marie-Christine Rio1
MMP11 overexpression is a bad prognostic factor in various human carcinomas. Interestingly, this 
proteinase is not expressed in malignant cells themselves but is secreted by adjacent non-malignant 
mesenchymal/stromal cells, such as cancer associated fibroblasts (CAFs) and adipocytes (CAAs), which 
favors cancer cell survival and progression. As MMP11 negatively regulates adipogenesis in vitro, we 
hypothesized that it may play a role in whole body metabolism and energy homeostasis. We used 
an in vivo gain- (Mmp11-Tg mice) and loss- (Mmp11−/− mice) of-function approach to address the 
systemic function of MMP11. Strikingly, MMP11 overexpression protects against type 2 diabetes 
while Mmp11−/− mice exhibit hallmarks of metabolic syndrome. Moreover, Mmp11-Tg mice were 
protected from diet-induced obesity and display mitochondrial dysfunction, due to oxidative stress, 
and metabolic switch from oxidative phosphorylation to aerobic glycolysis. This Warburg-like effect 
observed in adipose tissues might provide a rationale for the deleterious impact of CAA-secreted 
MMP11, favouring tumor progression. MMP11 overexpression also leads to increased circulating IGF1 
levels and the activation of the IGF1/AKT/FOXO1 cascade, an important metabolic signalling pathway. 
Our data reveal a major role for MMP11 in controlling energy metabolism, and provide new clues for 
understanding the relationship between metabolism, cancer progression and patient outcome.
More and more epidemiological data attribute a pernicious effect to metabolic disorders, notably obesity and dia-
betes, on cancer progression. Moreover, metformin, a drug commonly administered for type 2 diabetes, displays 
antitumor properties1. To date, most studies have emphasized tumor aggressiveness in a context of already consti-
tuted metabolic disorders. Less attention has been given to the ability of cancer cells to impact on metabolism via 
molecules abnormally expressed by primary tumors and/or metastases. This effect may be of interest and should 
therefore be evaluated to unravel the link between metabolism and cancer.
Matrix metalloproteinase 11 (MMP11; previously named stromelysin-3)2 belongs to a family of extracellular 
proteolytic enzymes involved in extracellular matrix (ECM) remodeling and activation of latent factors. While 
most MMPs require the presence of additive proteinases to be extracellularly activated, MMP11 is activated prior 
to secretion by Golgi-associated furin-like proteinases3,4. From a functional point of view, MMP11 is a unique 
member of the MMP family. Indeed, it is a very selective enzyme that does not cleave major components of the 
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ECM. To date, only three main substrates have been identified, namely the insulin-like growth factor-binding 
protein-1 (IGFBP-1)5, the laminin receptor6 and the native alpha3 chain of collagen VI7. This sharp specificity is 
probably due to its particular S1′ pocket structure looking like a tunnel running through the enzyme8.
MMP11 plays a role in various embryonic and adult physiological processes, including postnatal mammary 
gland development and function9. MMP11 also participates in human diseases, most notably cancers. MMP11 
overexpression occurs in various human invasive carcinomas including the common breast, prostate and colon 
cancers. High MMP11 levels correlate with tumor aggressiveness as well as with poor patient clinical out-
come10,11. Importantly, MMP11 is a tumor proteinase not expressed in the malignant epithelial cells, but in the 
non-malignant adjacent mesenchymal/stromal cells12. Chemically-induced12 or ras oncogene-induced13 mouse 
tumor models have shown that stromal MMP11 is a key factor for tumor progression. It lowers cancer cell death 
through anoikis during local invasion, favouring thereby cancer cell survival and implantation in connective 
tissues14–16. More recently, MMP11 was shown to be expressed by a newly defined cellular component of the 
tumor microenvironment, called the cancer-associated adipocytes (CAAs), in human cancers9,16,17. Moreover, 
in vitro, MMP11 reduces adipocyte differentiation and even reverts mature adipocyte differentiation16. Thus, 
invasive cancer cells induce proximal adipocytes to express MMP11 leading to their dedifferentiation into fibro-
blasts [reviewed in18]. Tumor resident adipocytes are therefore local regulators of cancer cell behavior via an « 
adipocyte-cancer cell paracrine loop (ACCPL) » occurring during the tumor invasive steps19. The molecular 
mechanisms involved remain largely unknown.
In this context, we hypothesized that the high amounts of MMP11 present in almost all invasive tumors might 
impact patient metabolism and energy homeostasis. We have addressed this question in the present study using a 
genetic strategy. Experiments have been done in the absence of malignancy to discard any possible tumor-related 
interfering effects. To do so, we developed a MMP11-overexpressing transgenic mouse strain (Mmp11-Tg). 
We also used MMP11 deficient mice (Mmp11−/− ) previously developed in our laboratory12. These gain- and 
loss-of-function models allowed us to examine the in vivo function of MMP11 in metabolism. Our data reveal 
that MMP11 impacts on lipid synthesis and in vivo storage in adipose tissues and liver, and protects Mmp11-Tg 
mice from diabesity. Highly supporting this MMP11 metabolic function, Mmp11−/− mice12 displayed a reverse 
phenotype with hallmarks of type 2 diabetes, most notably glucose intolerance and insulin resistance.
Results
Mmp11-Tg mice display decreased fat mass and improved metabolic parameters. We gener-
ated transgenic mice, which overexpressed a secreted form of mouse MMP11 (Mmp11-Tg, FVBN genetic back-
ground) in the skin, a highly vascularized organ (Fig. 1a, upper left panel). MMP11 protein was detected in skin 
homogenates from Mmp11-Tg mice, while no expression was detected in controls (Fig. 1a, lower left panel). 
Robust Mmp11 mRNA expression was confirmed as well (Fig. 1a, right panel). The level of expression was simi-
lar to that detected in human invasive tumors and/or metastases2,10. Interestingly, body weight was significantly 
decreased in young (8-week-old) and old (40-week-old) Mmp11-Tg mice compared to WT littermates (Fig. 1b), 
and the difference more pronounced in older mice. Metabolic profiling indicated that 12-week-old Mmp11-Tg 
mice had decreased levels of serum glucose, total cholesterol (mainly HDL-cholesterol), triglycerides and FFA 
(Fig. S1). Consistent with decreased circulating glucose levels, Mmp11-Tg mice exhibited enhanced glucose 
tolerance and insulin sensitivity compared to WT mice under normal diet conditions (Fig. 1c). Additionally, 
Mmp11-Tg mice displayed increased serum adiponectin levels and decreased leptin levels, consistent with the 
loss of body weight observed in mutant mice (Fig. 1d). Histological examination of the peri-gonadal white adi-
pose tissue (WAT) of Mmp11-Tg mice revealed aggregates of multilocular brown adipocyte-like cells, while the 
brown adipose tissue (BAT) exhibited less fat accumulation than that of control mice (Fig. 1e). Consistently, 
increased expression of the metabolic regulator and late BAT marker, peroxisome proliferator-activated receptor 
gamma (PPARγ )-coactivator 1α (Pgc1α)20, was observed (Fig. 1f). Increased expression of bone morphogenetic 
protein 7 (Bmp7), a protein that triggers commitment of mesenchymal progenitor cells to a brown adipocyte 
lineage21, but not Bmp4, which induces the commitment of mesenchymal cells into white preadipocytes22, was 
also noted (Fig. 1f). It is worth noting that the brown-like cells present in the WAT of Mmp11-Tg mice were not 
of “beige” origin since we did not observe any change in the expression of “beige” markers Cd137 and Cited 123,24, 
while they overexpressed BAT determining genes such as C/ebpβ , Prdm16 and Cidea23,25,26 (Fig. 1f). In addition, 
expression of the mitochondria DNA replication gene mitochondrial transcription factor A (Tfam) was also 
enhanced in Mmp11-Tg WAT compared to controls. Interestingly, these brown fat-like cells were also observed 
in the mammary gland adipose tissue of Mmp11-Tg mice (Fig. 1e). Furthermore, we observed decreased mRNA 
expression of the master adipose tissue differentiating factor Pparγ in the WAT but not in the BAT, and enhanced 
expression of Pgc1α in both tissues (WAT and BAT) without significant changes in the expression of its target 
gene uncoupling protein 1 (Ucp1) in the BAT (Fig. 1f). Thus, MMP11 triggers different molecular changes in the 
WAT and BAT.
These results indicated that MMP11 impacts whole body metabolism and favours fat browning.
Mmp11-Tg mice exhibit defective adaptive thermogenesis due to altered mitochondrial func-
tion. As increases in BAT-like cells could affect thermogenesis, we addressed the ability of Mmp11-Tg mice 
to maintain a normal body temperature when exposed to cold. After a 4h exposure to cold, Mmp11-Tg mice 
displayed an inability to maintain body temperature within a physiological range (Fig. 2a). Similarly, an injection 
of the β 3-adrenergic agonist BRL37344 showed an immediate increase in body temperature in WT animals while 
Mmp11-Tg animals presented a delayed response (Fig. 2b). Despite the presence of BAT-like cells within the 
WAT, Mmp11-Tg mice have altered adaptive thermogenesis showing that MMP11-induced BAT-like cells were 
not functional. As mitochondria are the most important supplier of ATP and the site of adaptive thermogenesis, 
we checked mitochondria structure and function in Mmp11-Tg mice. Ultrastructural analysis by transmission 
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Figure 1. Mmp11-Tg mice metabolic analyses. (a) Upper left panel, scheme of the transgene construct. 
Lower left panel, Western blot showing MMP11 expression in skin protein extracts from 12-week-old WT and 
Mmp11-Tg mice (n = 3/group); right panel, qRT-PCR analysis showing the robust increase in Mmp11 mRNA 
expression in Mmp11-Tg mice compared to controls (n = 5/group); (b) Body weight progression in 8- and 
40-week-old Mmp11-Tg and WT mice (n = 9/group); (c) IPGTT and IPIST analyses and AUC in Mmp11-Tg 
and WT mice under normal diet conditions; (d) Circulating adiponectin and leptin levels in Mmp11-Tg and 
WT mice (n = 8/group); (e) HE staining of gonadal WAT, mammary gland WAT and BAT histological sections 
from Mmp11-Tg and WT mice. The WAT of Mmp11-Tg mice displayed areas of multilocular brown adipocyte-
like cells compared to WT counterparts. The BAT of Mmp11-Tg mice accumulates smaller and less lipid 
droplets compared to WT animals; (f) Expression profile of genes involved in adipogenesis (n = 6–7/group).
www.nature.com/scientificreports/
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electron microscopy (TEM) showed the presence of proliferating mitochondria displaying altered cristae in BAT 
cells (Fig. 2c). Based on these observations, we hypothesized that impaired mitochondrial structure and function 
could be due to enhanced oxidative stress in the BAT of Mmp11-Tg mice. Indeed, we found a significant increase 
in thiobarbituric acid reactive substances (TBARS), a marker of lipid peroxidation, in the Mmp11-Tg BAT in 
comparison to controls (Fig. 2d). We then asked whether this oxidative stress was accompanied by an antioxidant 
defense mechanism. Indeed, we observed an increase in the enzymatic activities of glutathione peroxidase (GPx) 
and catalase (Fig. 2e), indicating a response to increased oxidative stress.
Since Mmp11-Tg mice had decreased circulating glucose levels and exhibited altered mitochondria, we 
investigated whether forced MMP11 expression could trigger aerobic glycolysis (i.e. a Warburg-like effect) in 
the BAT. Indeed, we found that the expression of genes encoding enzymes implicated in lactate production, like 
LDHA (Lactate Dehydrogenase A) and lactate uptake MCT1 (Monocarboxylate transporter 1), were increased 
in Mmp11-Tg mice (Fig. 2f). A significant upregulation of LDHB was further noted, suggesting that the lactate 
Figure 2. In vivo and in vitro impact of MMP11 on mitochondrial function. (a) Rectal body temperature 
progression in Mmp11-Tg and WT mice placed during 4 h at 4 °C (n = 5/group); (b) Variation in rectal body 
temperature as a function of time after injection of the β 3-adrenergic agonist BRL37344 in Mmp11-Tg and 
WT mice (n = 6/group); (c) TEM showed increased numbers of mitochondria and less fat in the BAT of 
Mmp11-Tg compared to WT mice. Many of the mitochondria displayed altered cristae (scale bar = 10 μ m 
in left panels and 2 μ m in right panels); the mitochondria count in the BAT is indicated (n = 5); (d) TBARS 
measurement in BAT of Mmp11-Tg and WT mice; (e) Glutathion peroxidase (GPx) and catalase enzymatic 
activities in the BAT of Mmp11-Tg and WT mice; (f) mRNA expression of genes involved in lactate metabolism 
and pyruvate metabolism (n = 6–8/group); (g) Study of mitochondria function in 3T3-L1 adipocytes treated 
24 h with vehicle, active-MMP11 or inactive-MMP11 (OXPHOS = oxidative phosphorylation using Seahorse 
technology, TMRM = tetramethyl rhodamine methylester for mitochondrial permeability test); (h) Oxygen 
consumption rate (OCR) measurement at baseline and after sequential injection of oligomycin (ATP synthase 
inhibitor), FCCP (uncoupler agent), and Rotenone/antimycin A (complex I/complex III inhibitors, respectively) 
in vehicle-, active-MMP11- and inactive-MMP11-treated 3T3-L1 preadipocytes; (i) Relative mitochondrial 
activity parameters (spare respiratory capacity, proton leak and ATP turnover) in vehicle-, active-MMP11- and 
inactive-MMP11-treated 3T3-L1 preadipocytes; (j) Mitochondrial permeability test as measured by TMRM 
fluorescence intensity, which inversely correlates with the mitochondrial depolarization.
www.nature.com/scientificreports/
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produced was most likely converted to pyruvate and used used as an energy fuel. The enhanced expression level 
of the pyruvate dehydrogenase (Pdh) complex, composed of Dld (dihydrolipoamide dehydrogenase), Pdh, and 
Dlat1 (dihydrolipoamide S-acetyltransferase) argues in favour of pyruvate transformation into acetyl coenzyme A 
(Fig. 2f).
Altogether, these results showed that MMP11 overexpression provoked mitochondrial defects in the BAT, 
which translated into thermogenesis defects and enhanced expression of glycolytic genes.
Recombinant MMP11 impairs mitochondrial activity and OXPHOS in 3T3-L1 preadipo-
cytes. Because of the altered mitochondria observed in the BAT of Mmp11-Tg mice, we next addressed the 
direct effect of MMP11 on mitochondrial function in vitro. 3T3-L1 preadipocyte cells were treated for 24 h with 
active or inactive MMP11 recombinant proteins and key parameters estimating the functionality of oxidative 
phosphorylation (OXPHOS) were measured (Fig. 2g). The oxygen consumption rate (OCR) was measured at 
baseline and after sequential injections of oligomycin (an ATP synthase inhibitor), the uncoupling agent FCCP 
(carbonylcyanide-4-trifluoromethoxyphenylhydrazone) and rotenone/antimycin A (complex I and III inhibitors, 
respectively). Cells treated with active MMP11 exhibited a significantly lower OCR after oligomycin treatment 
(Fig. 2h). FCCP treatment also yielded significantly lower maximal respiratory activity compared to cells treated 
with vehicle or inactive MMP11 (Fig. 2h). As a result, a significant decrease in the spare respiratory capacity (SRC) 
was observed in active MMP11-treated cells compared to vehicle- or inactive MMP11-treated cells (Fig. 2i). These 
data show that MMP11 treatment impairs the cellular response to increased energy demand. MMP11 signifi-
cantly decreased non-mitochondrial respiration (an important parameter for accurate mitochondrial respiration 
measurement) after injection of rotenone/antimycin A (Fig. 2h) together with a significant increase in proton 
leak (Fig. 2i), suggesting mitochondrial damage. Moreover, ATP turnover, which represents the rate of oxygen 
consumption due to mitochondrial ATP synthesis, was significantly decreased in active MMP11-treated cells 
(Fig. 2i). Consistent with the increase in mitochondrial proton leak, we observed a decrease in the intensity of the 
mitochondrial fluorescent dye tetramethylrhodamine methyl ester (TMRM) in active MMP11-treated cells indi-
cating an enhanced mitochondria permeability caused by membrane depolarization, a hallmark of metabolically 
stressed cells (Fig. 2j). Altogether, these in vitro data showed that MMP11 impacts negatively on mitochondrial 
respiratory activity and ATP production.
Our data thus demonstrate that MMP11 negatively affects mitochondrial function through enhanced oxida-
tive stress in vitro and in vivo, which results in a decrease in mitochondrial respiration and an increase in aerobic 
glycolysis.
MMP11 protects from diet-induced obesity (DIO). Having established that MMP11 overexpression 
modulates fat mass, we aimed to determine whether MMP11 overexpression could prevent the pathophysio-
logical impact of a high fat diet (HFD). Six-week-old Mmp11-Tg mice and control littermates were subjected 
to a HFD for six weeks. During this time, despite similar food intake (Fig. 3d, left panel), Mmp11-Tg mice were 
protected from excessive weight gain compared with control mice (Fig. 3a). In addition, under HFD conditions 
the weight gain differences between Mmp11-Tg and WT mice were more pronounced than under normal diet 
(ND) conditions. After 6 weeks of HFD, Mmp11-Tg mice exhibited less fat mass than control mice (Fig. 3a, upper 
panel) and an increase in total energy expenditure (TEE) (Fig. 3d, right panel). Mmp11-Tg mice had improved 
glucose tolerance and insulin sensitivity, as shown by a smaller area under the curve (AUC) in the intra-peritoneal 
glucose tolerance (IPGTT) and insulin sensitivity tests (IPIST) (Fig. 3b, left and right panels, respectively). 
Histological analysis of WAT sections from HFD Mmp11-Tg mice revealed smaller white adipocytes and areas 
of multilocular brown-like adipocytes compared to the hypertrophied adipocytes of HFD control mice (Fig. 3c, 
left upper panel). These observations were confirmed by TEM analysis (Fig. 3c, left lower panel). Similarly, the 
BAT from Mmp11-Tg mice contained very small lipid droplets and was highly enriched in mitochondria, some 
of which appeared altered (Fig. 3c, right panel).
We then checked the mRNA expression of genes implicated in the adipogenic program in the WAT of 
HFD-fed Mmp11-Tg mice. We observed increased expression of Bmp4 recently shown to promote WAT brown 
fat formation27 and some increase for the brown adipocyte marker Bmp721 (Fig. 3e). Expression levels of the 
brown adipocyte markers Pgc1α, Ucp1 and Cidea were also enhanced supporting that indeed MMP11 favours 
WAT browning. Interestingly, a decrease in the expression of Tnfα was observed, suggesting a protection against 
metabolic inflammation in the WAT of Mmp11-Tg mice (Fig. 3e). Further, an increase in the expression of the 
glucose transporter Glut4, Irs2 and adiponectin (Adipoq) was observed in the WAT of Mmp11-Tg mice, in accord-
ance with improved insulin sensitivity (Fig. 3e). Consistently, the livers of Mmp11-Tg mice were also protected 
from hepatic steatosis compared to WT livers (Fig. S2a upper panel). TEM analysis showed decreased number 
and size of liver lipid droplets in HFD-fed Mmp11-Tg mice (Fig. S2a lower panel). We observed an enhanced 
expression of β -oxidation genes such as Pparα and its target gene acyl coenzyme A oxidase (Aco) (Fig. S2b). 
Moreover, the expression levels of Pgc1α and of Foxo1 (forkhead transcription box O1, a transcriptional acti-
vator of PPARα) were increased. The expression levels of two known lipogenic genes, sterol response element 
binding protein 1c (Srebp1c) and carbohydrate response element binding protein (Chrebp), were also elevated 
(Fig. S2b). Increased expression of the fatty acid synthesis genes acetyl-Coenzyme A carboxylase 1 and 2 (Acc1 
and Acc2) was also noted, indicating an increased turnover of fatty acids in the Mmp11-Tg liver under HFD. 
Furthermore, HFD Mmp11-Tg liver displayed higher insulin sensitivity as demonstrated by an enhanced 
expression of Irs2.
In summary, MMP11 protects from excessive weight gain and hepatic steatosis through increased lipid mobi-
lisation and metabolism from fat and liver.
www.nature.com/scientificreports/
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Figure 3. Mmp11-Tg mice are resistant to HFD-induced metabolic syndrome. (a) Weight gain progression 
during 6 weeks of a HFD (n = 13/group) and fat mass measurement at 6 weeks (n = 8–9/group); (b) IPGTT 
(left panel) and IPIST (right panel) tests and AUC (n = 8–10/group) after 6 weeks of a HFD; (c) HE and TEM 
analyses of the WAT (left panel) and BAT (right panel) in Mmp11-Tg and WT mice under HFD; (d) Mean daily 
food intake over 4 days (n = 8–9/group) and total energy expenditure (TEE) quantification at week 5 of the diet 
(n = 8/group); (e) Metabolic gene expression profile in the WAT (n = 8/group).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:25140 | DOI: 10.1038/srep25140
MMP11 triggers IGF1 signalling via the IGF1/AKT/FOXO1 cascade in adipose tissue. To uncover 
the molecular mechanism(s) underlying MMP11 systemic function, we investigated the insulin/IGF1 axis, 
reported to be involved in metabolic disorders28. We observed a significant increase of about 20% in serum IGF1 
levels in Mmp11-Tg mice compared to WT animals (Fig. 4a), as well as increases in IGF1 protein levels in WAT 
and BAT extracts (Fig. 4b). In addition, increased interaction between IGF1 and its receptor IGF1Rβ was found 
in both WAT and BAT protein extracts (Fig. 4c). Consistently, increased tyrosine phosphorylation of the IGF1Rβ 
receptor (Y1150/1151) and serine phosphorylation of AKT (S473) indicated that the IGF1/IGF1Rβ pathway was 
more active in the WAT and BAT of Mmp11-Tg compared to WT (Fig. 4d). As a consequence, FOXO1 phospho-
rylation (S253), a target of AKT, was also significantly enhanced (Fig. 4d). The level of AKT and FOXO1 were 
modestly increased in the WAT but not in the BAT of Mmp11-Tg compared to WT mice (Fig. 4d and Fig. S3). 
Altogether, the overexpression of MMP11 enhances IGF1 bioavailability, which translates into activation of the 
IGF1/AKT cascade.
In addition to the activation of the IGF1/AKT/FOXO1 signalling pathway, MMP11 overexpression affected 
the expression of some genes of this pathway, albeit in the BAT but not in the WAT. Indeed, we observed an 
increase in Irs2 and a decrease in Grb10, a negative regulator of the insulin/IGF1 receptor pathway29, mRNA 
levels in the BAT (Fig. 4e). These observations are in line with an activation of the IGF1/AKT/FOXO1 cascade in 
Mmp11-Tg mice.
Figure 4. MMP11 activates the IGF1/AKT/FOXO1 axis. (a) Circulating IGF1 levels in Mmp11-Tg mice and 
controls (n = 8/group); (b) Immunoblots describing the expression of IGF1 in the WAT and BAT of Mmp11-Tg 
mice and controls; (c) Increased physical interaction between IGF1 and its receptor IGF1Rβ in the WAT 
and BAT of Mmp11-Tg compared to WT mice. Protein extracts were immunoprecipitated with an IGF1Rβ 
antibody and the interaction was revealed with an anti-IGF1 antibody; (d) left panel: Immunoblots for proteins 
involved in the IGF1 signalling pathway in the WAT and BAT of Mmp11-Tg mice compared to WT, right panel: 
quantification of the ratios of phosphorylated IGF1Rβ , pAKT, and pFOXO1 proteins relative to IGF1Rβ , AKT, 
and FOXO1, respectively, normalized to actin expression (data are presented as fold change of Mmp11-Tg 
values to WT values); (e) Expression profile of genes involved in the insulin/IGF1 pathway in the WAT and BAT 
of Mmp11-Tg and WT mice (n = 6–7/group).
www.nature.com/scientificreports/
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From these experiments, we conclude that MMP11 significantly increases IGF1 bioavailability to affect whole 
body metabolism.
Loss of MMP11 induces a metabolic syndrome. Given that MMP11 overexpression was associated with 
major metabolic changes, we asked if MMP11 deletion could mirror Mmp11-Tg phenotype. Under normal die-
tary conditions, we observed that young (8-week-old) and older (30-week-old) MMP11 knockout (Mmp11−/−) 
mice exhibited significantly increased body weight (Fig. 5a) compared to age-matched wild type mice (WT). 
With complete penetrance, 12-week-old Mmp11−/− mice displayed significantly increased serum glucose, insu-
lin, total cholesterol, triglycerides (TG) and, FFA levels (Fig. S4a), together with hyperleptinemia and hypoadi-
ponectinemia (Fig. 5d), suggestive of a metabolic syndrome phenotype. The levels of circulating IGF1 were also 
decreased in Mmp11−/− mice (Fig. 5d). Supporting these data, Mmp11−/− mice showed decreased glucose tol-
erance (Fig. 5b) and insulin sensitivity (Fig. 5c) compared to control mice. Semi thin sections of Mmp11−/− mice 
showed hypertrophied adipocytes in the WAT and increased fat depots in the BAT as compared to WT animals 
(Fig. 5e, upper panels). TEM analysis confirmed that Mmp11−/− BAT tissues accumulate significantly more lipid 
droplets compared to control mice (Fig. 5e, lower panels). Analysis of a subset of key metabolic genes including 
Pparγ revealed a drastic increase in their mRNA expression in the WAT (Fig. 5f). Leptin gene expression was 
also increased in Mmp11−/− WAT, while adiponectin expression was decreased. Consistent with the findings of 
increased FFA levels, we observed increased mRNA expression of the adipose triglyceride lipase (Atgl) lipolytic 
enzyme in the WAT of Mmp11−/− compared to WT mice (Fig. 5f). We also observed a significant increase in the 
expression of Grb10 in the WAT of Mmp11−/− mice (Fig. 5f). Collectively, these results indicate enhanced adi-
pogenesis in Mmp11−/− mice, which mirrors the Mmp11-Tg phenotype and strengthens the specific impact of 
MMP11 on adipose tissue metabolism. Consistent with decreased circulating IGF1 levels, the IGF1/AKT/FOXO1 
signalling pathway was under-activated in the WAT of Mmp11−/− mice compared to WT animals (Fig. S4b).
Histological analysis of the livers of 12-week-old Mmp11−/− mice using oil red O staining revealed enhanced 
lipid droplet accumulation (Fig. S4c), and increased total triglyceride content (Fig. S4d), evoking hepatic steatosis. 
Consistently, we observed increased mRNA expression of Pparγ, fatty acid synthase (Fas), Srebp1c and Chrebp in 
the liver (Fig. S4e). We did not observe any changes in the expression of the β -oxidation gene Pparα (Fig. S4e). 
Moreover, increased expression of genes encoding the gluconeogenic enzymes glucose-6 phosphatase (G6Pase) 
and phosphoenolpyruvate carboxykinase (PCK1) was noted, together with a significant increase in the expression 
of Foxo1, a positive regulator of PCK1 and G6Pase in the liver30,31 (Fig. S4e). Consistent with a decrease in circu-
lating IGF1 (Fig. 5d), we observed a concomitant increase in the expression of IGF-binding protein-1 (Igfbp1) in 
the livers of Mmp11−/− mice compared to controls (Fig. S4f). This supports the notion that MMP11 deficiency 
impacts on the insulin/IGF1-signalling pathway, through negative modulation of IGF1 bioavailability. Hence, a 
drastic decrease in AKT phosphorylation in the livers of MMP11-deficient animals compared to control mice was 
noted (Fig. S4g). Thus, MMP11 plays an important role in glucose and lipid metabolism as MMP11 ablation in 
mice induces diabesity with metabolic syndrome features and insulin resistance.
Discussion
This study used gain- and loss-of-function in vivo models (Mmp11-Tg and Mmp11−/− mice, respectively) to 
uncover the role of MMP11 in whole body metabolism. We demonstrated that MMP11 plays a systemic role in 
the regulation of glucose and lipid homeostasis, which led to insulin sensitivity and protection from diabesity.
Although several studies have linked changes in MMP expression to obesity and insulin resistance, different 
MMPs have distinct activities. Likewise, insulin resistance and expanded adiposity induced by a sucrose-rich diet 
are associated with decreases in MMP2 and MMP9 in mouse adipose tissue32. In vitro, MMP2 promotes adipo-
genesis33, while MMP9 has no effect on adipocyte differentiation34. In human type 2 diabetes patients, MMP2 and 
MMP9 plasma levels are higher than those reported for healthy individuals35. MMP13 is linked to diet-induced 
obesity in mice and adipogenesis in vitro36. In addition, decreased MMP3 has been observed in the adipose tissue 
of retinoic acid receptor (RAR)-related orphan receptor gamma deficient (RORγ −/−) mice, which is associated 
with increased adipocyte formation and improved insulin sensitivity in diet-induced-obesity37. Furthermore, 
tissue inhibitors of MMPs (TIMPs) are also concerned. TIMP1 is increased in the serum and adipose tissue 
of obese mouse models, and TIMP1 injections in nutritionally-challenged mice lead to enlarged adipocytes38. 
Human type 2 diabetes patients exhibited increased plasma levels of TIMP1 and TIMP237. On the other hand, 
TIMP3 deficiency in insulin receptor-haploinsufficient mice promotes type 2 diabetes and vascular inflamma-
tion39. Nonetheless, MMP11 appears to be unique in protecting against diabesity.
At the molecular level, we reported an approximate 20% increase in circulating IGF1 protein in Mmp11-Tg 
mice. Small variations in IGF1 have been shown to be significant in vivo. For example, a 7–8% increase in serum 
IGF1 constitutes a predictor of risk for prostate cancer40. Whether increased IGF1 bioavailability subsequent 
to MMP11 overexpression is a direct or indirect event will be difficult to decipher in vivo. Nevertheless, IGF1 
levels are decreased in Mmp11−/− mice strongly supporting that MMP11 is responsible for IGF1 changes. 
Moreover, it is noteworthy that changes in IGF1 bioactivity are attributed to its release from IGF-binding proteins 
(IGFBPs), less than 5% of IGF1 being free in the plasma41,42. As IGFBP1 is one of the rare identified MMP11 
substrates, MMP11 might regulate free IGF1 levels via IGFBP1 cleavage. Indeed, it has been shown in vitro that 
MMP11-dependent IGFBP1 cleavage leads to IGF1 release5.
Despite the positive effects of MMP11 on glucose homeostasis, MMP11 overexpression is linked to impaired 
mitochondrial function in the BAT due to increased oxidative stress and augmented expression of genes 
involved in aerobic glycolysis. Accordingly, additional in vitro experiments revealed that treatment of preadi-
pocytes with recombinant MMP11 protein caused an alteration in mitochondrial function with a decrease in 
OXPHOS-mediated ATP production and enhanced proton leak. Mechanistically, this oxydative stress could be 
due to the MMP11-mediated increase in IGF1 bioavailability and consequent activation of IGF1/AKT/FOXO1 
www.nature.com/scientificreports/
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Figure 5. MMP11 deficiency promotes diabesity. (a) Increased body weight in 8- and 30-week-old 
Mmp11−/− mice compared to age-matched WT counterparts (n = 10/group); (b) IPGTT test in Mmp11−/− 
and WT mice (n = 8/group); (c) IPIST test in Mmp11−/− and WT mice (n = 8/group); (d) Circulating 
adiponectin, leptin and IGF1 levels in Mmp11−/− and WT mice (n = 8/group); (e) Toluidine blue staining 
(upper panels) and ultrastructure (lower panels) of WAT and BAT. Semi-thin sections (scale bar = 50 μ m) 
and TEM (scale bar = 10 μ m) showed hypertrophied white adipocytes in Mmp11−/− mice compared to WT 
mice. Mmp11−/− brown adipocytes accumulate more fat than WT cells; (f) Metabolic gene expression profile 
changes in the WAT of Mmp11−/− and WT mice (n = 5–7/group); (g) Summary of the metabolic abnormalities 
observed in Mmp11-Tg and Mmp11−/− mice; (h) A proposed model of the MMP11-induced metabolic switch 
from mitochondrial respiration to aerobic glycolysis. MMP11 induces an increase in IGF1 bioavailability. The 
subsequent increase in the IGF1/AKT signalling provokes an increase in oxidative stress (ROS) which impairs 
mitochondrial respiration (OXPHOS), and an increase in aerobic glycolysis producing lactate that can be used as 
a complementary source of energy for the cell itself or for neighboring cells via the MCT4/MCT1 shuttle. Fatty 
acid oxidation is also increased and represents a metabolic fuel as well. TCA: tricarboxylic acid cycle.
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signalling in the adipose tissue. Supporting this hypothesis, activated AKT has been shown to promote intra-
cellular ROS accumulation43 and induce aerobic glycolysis both in non-transformed cells44 and in cancer cells 
along with increased lactate production45. This MMP11-induced reduction in OXPHOS may provoke a substan-
tial increase in systemic metabolism when energy demand is increased, thereby depleting adipose tissue lipid 
reserves. Furthermore, the browning of the WAT in Mmp11-Tg animals could be due to increased IGF1 signal-
ling, as this pathway has been shown to positively regulate brown fat differentiation through two complemen-
tary pathways, RAS/ERK/CREB and PI3K/AKT/FOXO146. To date, only one report links a metalloproteinase to 
mitochondrial dysfunction, as abnormalities in mitochondrial ultrastructure, impaired respiration and increased 
lipid peroxidation were observed during post-ischemic reperfusion in the heart of mice with cardiac specific 
overexpression of MMP247.
Finally, our data highlight an unexpected important point. It is well established that aerobic glycolysis known 
as the “Warburg effect” is a hallmark of cancer cells to increase their biomass while decreasing OXPHOS48. Our 
data provide a rationale for the deleterious effects of MMP11 on human carcinomas. Given that MMP11 is over-
expressed in almost all invasive cancers, we speculate that the effect of MMP11 overexpression observed in the 
adipose tissue of Mmp11-Tg model could recapitulate the metabolic changes observed in CAAs and CAFs19. This 
metabolic switch may provide cancer cells with metabolites such as fatty acids as we observed also increased BAT 
expression of the gene encoding the fatty acid oxidation enzyme long chain acyl Coenzyme A dehydrogenase or 
LCAD (data not shown) or through aerobic glycolysis (e.g. lactate). This energy transfer concept from CAFs to 
cancer cells is thought to occur after a ROS-induced catabolic response in CAFs that provides cancer cells with 
extranutrients to promote tumor progression49. Hence, due to the fact that MMP11 is expressed very early in 
tumor invasion processes, MMP11 could be one essential factor that initiates this metabolic reprogramming in 
CAAs and CAFs.
In conclusion, we provide in vivo evidence that MMP11 protects from diabesity (Fig. 5g) and promotes a 
metabolic switch from OXPHOS-induced ATP production to aerobic glycolysis to provide cells with comple-
mentary fuels to glucose (e.g. lactate, fatty acids) (Fig. 5h). We therefore propose that MMP11 be considered as an 
adipokine, which exerts an important systemic function under physiological conditions.
Material and Methods
Generation of mice. Mmp11−/− mice (on a 129 svJ genetic background) were previously described12. 
Mmp11-Tg mice express full-length mouse Mmp11. More details are provided in the supporting experimental 
procedure section. Mice were backcrossed 10 times onto the FVBN genetic background.
Thermogenesis analyses. Body rectal temperature (BRT) was measured in Mmp11-Tg and control mice 
(n = 5/group) before placing the mice in a cold room (4 °C). BRT was then measured regularly at intervals of 
1 h, up to 4 h. Mice were then placed in a normal temperature. For β 3-adrenergic-induced thermogenesis, mice 
were injected intraperitoneally (i.p.) with BRL37344 (Sigma-Aldrich, France) and BRT was measured up to 3 h 
at intervals of 30 min.
Histological analysis of liver and adipose tissue. Liver and adipose tissues (white: WAT and brown: 
BAT) were fixed immediately after sacrifice in paraformaldehyde 4% and then paraffin-embedded. 5 μ m sections 
were stained with Hematoxylin & eosin (HE) and oil red O (for liver sections), and observed under a Leica™ light 
microscope.
Transmission electron microscopy (TEM). Tissues were fixed in 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (pH 7.2) for 24 hr at 4 °C, washed in 0.1 M cacodylate buffer for 30 min and post-fixed in 1% 
osmium tetroxide in 0.1 M cacodylate buffer for 1 hr at 4 °C. Following stepwise dehydration with increasing con-
centrations of ethanol and embedding in Epon 812, ultrathin sections (70 nm) were stained with uranyl acetate 
and lead citrate, and observed with a Morgagni 268D electron microscope.
Mitochondrial function, western blot, enzymatic assays and RT-Q-PCR analyses methods are detailed in the 
supporting experimental procedures section associated to this manuscript.
This study has been approved by the IGBMC ethical committee for animal experimentation (Com’Eth). All 
methods were carried out in accordance with the approved guidelines
Statistics. Results are expressed as mean ± standard error of mean (SEM). Statistical analyses were performed 
using a two-tailed Student’s t test for independent samples. Results were considered statistically significant when 
the p-value was < 0.05. The degree of statistical significance was noted as: *p < 0.05, **p < 0.01, ***p < 0.001. All 
experiments were repeated independently at least 3 times.
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